Previous close | 5.68 |
Open | 5.94 |
Bid | 6.50 |
Ask | 7.00 |
Strike | 25.00 |
Expiry date | 2024-12-20 |
Day's range | 5.59 - 5.94 |
Contract range | N/A |
Volume | |
Open interest | 220 |
Prothena (PRTA) announces that Bristol Myers is exercising its option for the second time, thereby in-licensing exclusive global rights for PRX019 to potentially treat neurodegenerative diseases.
DUBLIN, May 28, 2024--Prothena today announced that Bristol Myers Squibb obtained the exclusive global license for PRX019 and will pay Prothena $80 million.
Celebrations may be in order for Prothena Corporation plc ( NASDAQ:PRTA ) shareholders, with the analysts delivering a...